Member Info for TorquayFan

That's better Ruck !
You've woken up now after a few good cups of coffee no doubt.
Your post rec'd. Should be an interesting week . . .

Bobbust . . .''SCLP.GB.PL on lse is Scancell on the NEX exchange. Looks like lse have incorporated NEX records for dual listed stocks. . . . .''

That was from Berm elsewhere last week. GLA

Thank you very much indeed re. GC.

So that's Tuesday night for most - 1 minute after midnight (then being Wednesday, just) and 7 am for me in Th. on Wednesday. I usually wake early and listen to 'The World Tonight' and 'The Archers' before walking the dogs and taking breakfast.

That'll fit in nicely which is probably why CRUK timed it like that (wink).

A nice weekend to you and all . . . .

I couldn't find the date/time on the CRUK website - please can anyone give me the source of that announcement of the 1timing again? Thanks.

Keep going M8 ! Every little helps . . .

The words of Jack Johnson are in my head - ''if only I could now''.

But I'd better pay HMRC instead. Goodnight

Just a snippet . . .

https://pharmaphorum.com/news/fda-decisions-could-slow-to-crawl-because-of-government-shutdown/?

Good point C7. The trial was revised to be both USA and UK ?
It WOULD be great if the trial commenced somewhere ! ASAP

https://pharma.elsevier.com/pharma-rd/government-shutdown-means-drugs-wait-safety-monitoring-continue/

Hard to tell but this may be holding up the FDA approval of our trial . . From Bermuda :-

“Consequently, the FDA has suspended reviews of existing Investigational New Drug (IND) and Biologics License Application (BLA) applications not covered by user fees, and is not reviewing applications for new drugs and biologics submitted during the shutdown period, except for emergency INDs and BLAs.”

hTTps://pharma.elsevier.com/pharma-rd/government-shutdown-means-drugs-wait-safety-monitoring-continue/

Scancell have an excellent chance of getting an award - such an outstanding team and an amazing project which may give rise at some time to the other issues that Trinity Delta refer to - IMO that'll then be a welcome distraction.

Roll on next Wednesday !

(WW yes but we win it or not - the GC 'asset' doesn't exist until (if) we do. The Trinity Delta comments are not relevant to Scancell's chances of winning an award - they comment on issues that might arise later. I see what's going on). ATB

The header to the para on Page 18 of the Trinity Delta report was this, ''We wonder whether winning the Grand Challenge Prize would be an unnecessary distraction''. Just MO but that's not a comment on Scancell's chances of winning a GC award is it ?

The reservation is, ''the commercial benefits of potentially being awarded the grant is less clear given uncertainty about who would own the data and the intellectual property arising from the programme''.

Now with respect, that isn't a comment on Scancell's chances of winning a GC award either is it ?

So Maths Prof, Tommy, Knowlesi and WW - I hope and don't think you are correct in downplaying Scancell's GC chances. Good to be cautious of course but IMO Scancell have every chance - just look at the 'Team' and how the project compares with the others shortlisted . . .

Nil desperandum !

http://docs.wixstatic.com/ugd/07354c_b3b393d919ad412aabb576db17467d6a.pdf

Inan - 3 buys reported on .GB.PL which are not reported here ?

In that link provided by WF, you can sense real excitement at CRUK - Dr Foulkes talks of the applications being, 'incredibly inspiring'. Dr Klausner talks of 'some of the best Researchers in the World'. I'm just observing that these are heady words from Gentlemen of such importance - let's hope they are thinking of Scancell's application in particular !

Dr Iain Foulkes, Executive Director of research and innovation at Cancer Research UK, said: “Round two of Grand Challenge is proving to be incredibly inspiring and the ambitious applications reflect the quality of global researchers this initiative has attracted to beat cancer sooner. We are delighted with the teams we have shortlisted and look forward to hearing more about how they plan to tackle the toughest challenges in cancer research.”

Dr Rick Klausner, Chair of Cancer Research UK’s Grand Challenge advisory panel, said: “The challenges set for Grand Challenge have once again attracted some of the best researchers in the world. I am looking forward to see how global collaboration could bring together diverse expertise, invigorate areas of research and overcome barriers in ways that are not happening at this point in time.”

Well that's the chickens counted - again . . . GLA

Post rec. Born from past experience with Scancell. We are 'RNS' weary in that respect . . . .
Just MOHO but a Grand Challenge award is external 'validation' of Scancell's direction so I hope you are not right.

Keep right on 'till the end of the road. GLA

Nice to see you're around. GL

After spending $232 per share on Loxo, interesting comment from the CEO :-

''Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop. In an interview with Reuters,
Ricks said that the company would rather focus on conventional drugs than chimeric antigen receptor T-cell (CAR-T) therapies, which are expensive to manufacture and are limited to a small group of patients.

Ricks has been in post now for two years after taking over from John Lechleiter, and is beginning to make his mark on the company, most notably with this month’s $8 billion acquisition of cancer drugs firm Loxo. And while there is plenty of scope for more buys, Ricks is ruling out purchasing firms developing CAR-Ts and other gene therapy based treatments, which are proving expensive and complex to make and difficult to market.

He told Reuters: “The data is amazing, but practically, it’s not reaching many people.”

https://pharmaphorum.com/news/lillys-ceo-looks-to-ma-but-not-for-car-t-or-gene-therapies/?

WF - from your link, ''Rothwell published a study earlier this year showing an increased risk of internal bleeding in people over 75 who take aspirin regularly.'' Aspirin has had a rough ride, maybe pushed by Pharma, because it is so cheap to produce. As a youngster, Mum would prescribe aspirin of 250 mg for a headache, flu etc., without a second thought. Current low dose aspirin are just 80mg and soluble.

As it happens, I take aspirin, one in the morning and one at night, dissolved in a full glass of water, as a blood thinning agent. If there are any benefits re. cancer incidence then hip hooray, but it will be a long time in the proving.

The alternative is the legendary 'Warfarin' which I used with surprisingly undesirable side effects, or new generation say 'Dabigatran', very expensive and includes a side effect of bleeding, which may be in the brain - plus bleeding then has to be stopped with a transfusion of platelets. So I use aspirin - in the IMO unlikely event of a bleed, you just stop taking it !

Pharma's anti-aspirin push means that some Chemists don't stock it at all now in both the UK and Thailand - there is something more profitable they can sell.

I Calvert - WF is right that a targeted rather than incidental treatment for cancer is fantastic by comparison, but I think Prof. Cuzick may be right too. Maybe aspirin does help in some cancers. I've certainly read snippets to that effect over the years. Incidentally.

IMO aspirin is much maligned.

Nagarajan's Phd thesis, just 260 pages - good to read with a cuppa tea. I see Prof Lindy gets special thanks in his acknowlegements for use of the 'Immunobody' vaccine.

Jacob Plieth - ''Three times now during #JPM19 I've come across anti-PD-(L)1 being developed not for itself but just as a combo "tool".''

Dr. Zoidberg - ''We need a colloquial term for this type of approach. “Marriage drug”? “Alliance biologic”?''

How about ''Immunobody facilitator'' ?? (That's mine BTW).

https://twitter.com/JacobPlieth/status/1083157843354603520

If this link doesn't work - someone please. GLA

These deals have been discussed here already but here's an FB take on it . . As Genentech increase their commitments to CAR-T here goes Sanofi with BioNTech themselves ?

''We start this week with two deals that illustrate the evolution of Sanofi's oncology R&D strategy. Sanofi centered its strategy on Regeneron when it struck a big deal with its longtime partner in 2015 but is now shifting its focus. The 2015 Regeneron deal is dead, replaced by an agreement that gives Sanofi an option on two assets but no discovery-stage relationship. Days before disclosing the news, Sanofi extended its cancer collaboration with BioNTech as part of a deal that saw it invest €80 million ($91 million) in the German mRNA specialist.''

1. Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact

Sanofi is paying Regeneron $462 million (€404 million) to exit the immuno-oncology pact it formed in 2015. The move gives Sanofi the right to opt in to two bispecific programs but otherwise leaves each company free to operate independently.

2. Sanofi invests €80M in BioNTech as cancer mRNA hits clinic

Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to start clinical development of the first cancer immunotherapy to emerge from their 2015 pact.

https://www.fiercebiotech.com/biotech/eurobiotech-report-sanofi-inks-oncology-deals-basilea-data-black-diamond-and-sirion?utm_source=internal&utm_medium=rss